Long COVID is best understood as a collection of overlapping symptoms rather than a single post-viral condition, suggests a ...

Obstructive sleep apnea (OSA) is a common sleep disorder in the U.S. affecting tens of millions, with estimates ranging from 25 to more than 80 million adults. However, most remain unaware they have ...

CVCT 2025: Cleerly Late-Breaking Science Identifies Thresholds of High Plaque Burden in Non-Obstructive CAD that May Carry Greater Risk Than Obstructive Disease Sixth late-breaking presentation from ...

Introduction: This study systematically investigated the relationship between body mass index (BMI) and lung function, incorporating Z-scores, thereby offering a novel approach to lung function ...

Of the 43% of study participants without pre-existing lung conditions, 70% had normal PFTs, 16% had obstructive pattern, 12% restrictive pattern, and 2.3% mixed pattern. After recovering from mild to ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

Maybe you know you snore like a bear, but you don’t feel much urgency to look into it. Or maybe you have been told to wear a continuous positive airway pressure, or CPAP, machine for sleep apnea, but ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

Credit: Getty Images Researchers explored the link between COVID-19 severity and PFT abnormalities, seeking factors to inform management of persistent respiratory issues. Of the 43% of study ...

Sept 29 (Reuters) - The U.S. Federal Reserve needs to maintain a restrictive stance of monetary policy to get inflation down to its 2% target, Cleveland Fed President Beth Hammack told CNBC's Squawk ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...